Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington’s disease: a review of clinical trial data

45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study

(2019) Robert A. Hauser et al.   CNS SPECTRUMS

Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia

(2019) Hubert H. Fernandez et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States

(2019) Anita M. Loughlin et al.   PLoS One

Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States

(2018) Victor W. Sung et al.   CURRENT MEDICAL RESEARCH AND OPINION

VMAT2 inhibitors for the treatment of tardive dyskinesia

(2018) Laura M. Scorr et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm

(2018) Roongroj Bhidayasiri et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Tardive syndromes

(2018) Daniel Savitt et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Valbenazine for the treatment of tardive dyskinesia

(2017) Lauren C. Seeberger et al.   EXPERT OPINION ON PHARMACOTHERAPY

Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

(2017) Leslie Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use

(2017) Maren Carbon et al.   JOURNAL OF CLINICAL PSYCHIATRY

The Effects of Valbenazine in Participants with Tardive Dyskinesia

(2017) Stewart A. Factor et al.   JOURNAL OF CLINICAL PSYCHIATRY

Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites

(2017) Dimitri E. Grigoriadis et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Randomized controlled trial of deutetrabenazine for tardive dyskinesia

(2017) Hubert H. Fernandez et al.   NEUROLOGY

Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea

(2017) Samuel Frank et al.   JAMA Neurology

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease

(2016) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study

(2015) Christopher F. O'Brien et al.   MOVEMENT DISORDERS

Tardive dyskinesia (syndrome): Current concept and modern approaches to its management

(2015) Paul P. Lerner et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Chorea associated with Huntington's disease: To treat or not to treat?

(2014) Joseph Jankovic et al.   MOVEMENT DISORDERS

Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model

(2014) Souha Mahmoudi et al.   MOVEMENT DISORDERS

Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine

(2014) S. A. Factor et al.   NEUROLOGY

Clinical Neurogenetics

(2013) Yvette M. Bordelon   NEUROLOGIC CLINICS

Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology

(2013) R. Bhidayasiri et al.   NEUROLOGY

Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults

(2011) Alicia Ruelaz Maher et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Vesicular monoamine transporters: Structure-function, pharmacology, and medicinal chemistry

(2010) Kandatege Wimalasena   MEDICINAL RESEARCH REVIEWS

Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial

(2010) Stanley N. Caroff et al.   NEUROLOGIC CLINICS